{"id":"https://openalex.org/W2158169126","doi":"https://doi.org/10.1182/blood-2005-09-3852","title":"Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKK\u03b2","display_name":"Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKK\u03b2","alternate_titles":[],"publication_year":2006,"publication_date":"2006-01-27","ids":{"openalex":"https://openalex.org/W2158169126","doi":"https://doi.org/10.1182/blood-2005-09-3852","mag":"2158169126","pmid":"https://pubmed.ncbi.nlm.nih.gov/16439676"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2005-09-3852","doi":"https://doi.org/10.1182/blood-2005-09-3852","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2005-09-3852","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2158169126"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1182/blood-2005-09-3852","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066214466","display_name":"Kumiko Nagashima","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kumiko Nagashima","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057308948","display_name":"Vito G. Sasseville","orcid":"https://orcid.org/0000-0003-2852-7931","observed_orcids":["https://orcid.org/0000-0003-2852-7931"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vito G. Sasseville","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015668234","display_name":"Danyi Wen","orcid":"https://orcid.org/0000-0002-3740-7117","observed_orcids":["https://orcid.org/0000-0002-3740-7117"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Danyi Wen","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028910801","display_name":"Andrew Bielecki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew Bielecki","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103179120","display_name":"Hua Yang","orcid":"https://orcid.org/0000-0002-7248-9410","observed_orcids":["https://orcid.org/0000-0002-7248-9410"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hua Yang","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069634023","display_name":"Chris Simpson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chris Simpson","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028715258","display_name":"Ethan P. Grant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ethan Grant","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026720857","display_name":"Michael E. Hepperle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Hepperle","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000432213","display_name":"Gerry Harriman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gerry Harriman","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072710886","display_name":"Bruce Jaffee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bruce Jaffee","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026965011","display_name":"Tim Ocain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tim Ocain","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103213863","display_name":"Yajun Xu","orcid":"https://orcid.org/0000-0002-5205-0187","observed_orcids":["https://orcid.org/0000-0002-5205-0187"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yajun Xu","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103574713","display_name":"Christopher C. Fraser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christopher C. Fraser","raw_affiliation_strings":["From Millennium Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From Millennium Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4405270001"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405270001"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":{"value":5500,"currency":"USD","value_usd":5500},"fwci":3.3006,"has_fulltext":false,"cited_by_count":93,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.93473549,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"107","issue":"11","first_page":"4266","last_page":"4273"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11591","display_name":"NF-\u03baB Signaling Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10371","display_name":"Immune Response and Inflammation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ikkbeta-inhibition","display_name":"IKK\u03b2 inhibition","score":0.765999972820282},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.859000027179718},{"id":"https://openalex.org/keywords/tnf-receptor-1","display_name":"TNF receptor 1","score":0.7760000228881836},{"id":"https://openalex.org/keywords/tnf-receptor-2","display_name":"TNF receptor 2","score":0.8259999752044678},{"id":"https://openalex.org/keywords/lymphodepletion","display_name":"lymphocyte depletion","score":0.9319999814033508},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.6499999761581421},{"id":"https://openalex.org/keywords/thymocyte-depletion","display_name":"thymocyte depletion","score":0.8420000076293945},{"id":"https://openalex.org/keywords/granulocytes","display_name":"granulocytes","score":0.7940000295639038},{"id":"https://openalex.org/keywords/bone-marrow","display_name":"bone marrow","score":0.6570000052452087},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.6290000081062317},{"id":"https://openalex.org/keywords/inflammatory-disease-therapy","display_name":"inflammatory disease therapy","score":0.4830000102519989}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7586880922317505},{"id":"https://openalex.org/C100175707","wikidata":"https://www.wikidata.org/wiki/Q6103519","display_name":"I\u03baB kinase","level":4,"score":0.629331111907959},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.6014052033424377},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5186947584152222},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5082030296325684},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.4992988109588623},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.4665946960449219},{"id":"https://openalex.org/C2779708716","wikidata":"https://www.wikidata.org/wiki/Q21110955","display_name":"Tumor necrosis factor receptor 1","level":4,"score":0.41340014338493347},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39884471893310547},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.3826110363006592},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.37293243408203125},{"id":"https://openalex.org/C2777730290","wikidata":"https://www.wikidata.org/wiki/Q411114","display_name":"NF-\u03baB","level":3,"score":0.3701291084289551},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3209291696548462},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.14280402660369873},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C93880895","wikidata":"https://www.wikidata.org/wiki/Q2579343","display_name":"Tumor necrosis factor receptor","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001402","descriptor_name":"B-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001854","descriptor_name":"Bone Marrow Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006098","descriptor_name":"Granulocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006098","descriptor_name":"Granulocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006412","descriptor_name":"Hematopoietic Stem Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008212","descriptor_name":"Lymphocyte Depletion","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D018124","descriptor_name":"Receptors, Tumor Necrosis Factor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018345","descriptor_name":"Mice, Knockout","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047888","descriptor_name":"Receptors, Tumor Necrosis Factor, Type I","qualifier_ui":"Q000172","qualifier_name":"deficiency","is_major_topic":false},{"descriptor_ui":"D047888","descriptor_name":"Receptors, Tumor Necrosis Factor, Type I","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D047889","descriptor_name":"Receptors, Tumor Necrosis Factor, Type II","qualifier_ui":"Q000172","qualifier_name":"deficiency","is_major_topic":false},{"descriptor_ui":"D047889","descriptor_name":"Receptors, Tumor Necrosis Factor, Type II","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051550","descriptor_name":"I-kappa B Kinase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D053319","descriptor_name":"Tumor Necrosis Factor Decoy Receptors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1182/blood-2005-09-3852","doi":"https://doi.org/10.1182/blood-2005-09-3852","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2005-09-3852","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},{"id":"pmid:16439676","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16439676","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1182/blood-2005-09-3852","doi":"https://doi.org/10.1182/blood-2005-09-3852","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2005-09-3852","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":57,"referenced_works":["https://openalex.org/W1486878670","https://openalex.org/W1501881225","https://openalex.org/W1530165617","https://openalex.org/W1534360145","https://openalex.org/W1548219170","https://openalex.org/W1568951543","https://openalex.org/W1621475458","https://openalex.org/W1652264402","https://openalex.org/W1722673048","https://openalex.org/W1759028523","https://openalex.org/W1966828006","https://openalex.org/W1968108602","https://openalex.org/W1975773646","https://openalex.org/W1976382352","https://openalex.org/W1977348505","https://openalex.org/W1980300702","https://openalex.org/W1982062664","https://openalex.org/W1983398697","https://openalex.org/W1985534077","https://openalex.org/W1985831147","https://openalex.org/W1988463809","https://openalex.org/W1991401793","https://openalex.org/W1991868611","https://openalex.org/W2007827117","https://openalex.org/W2032383673","https://openalex.org/W2033018194","https://openalex.org/W2034915619","https://openalex.org/W2042166751","https://openalex.org/W2043892945","https://openalex.org/W2046056065","https://openalex.org/W2053372168","https://openalex.org/W2053480920","https://openalex.org/W2054058504","https://openalex.org/W2057942179","https://openalex.org/W2062205148","https://openalex.org/W2064711537","https://openalex.org/W2079607078","https://openalex.org/W2081367726","https://openalex.org/W2086189875","https://openalex.org/W2087877138","https://openalex.org/W2095013915","https://openalex.org/W2104324075","https://openalex.org/W2106877484","https://openalex.org/W2118994799","https://openalex.org/W2124076790","https://openalex.org/W2137035181","https://openalex.org/W2141290206","https://openalex.org/W2147921405","https://openalex.org/W2159868799","https://openalex.org/W2159891151","https://openalex.org/W2160547697","https://openalex.org/W2166525118","https://openalex.org/W2169930621","https://openalex.org/W2170430559","https://openalex.org/W2331176038","https://openalex.org/W2470223656","https://openalex.org/W4229704949"],"related_works":["https://openalex.org/W2566943937","https://openalex.org/W2274316473","https://openalex.org/W1975773646","https://openalex.org/W2135279645","https://openalex.org/W2145559871","https://openalex.org/W4313350019","https://openalex.org/W1933542063","https://openalex.org/W2588360280","https://openalex.org/W1014048480","https://openalex.org/W2899934988"],"abstract_inverted_index":{"The":[0],"transcription":[1],"factor":[2],"NF-kappaB":[3,40],"plays":[4],"a":[5,15,23,83,153],"central":[6],"role":[7],"in":[8,43,66,71,73,95,102,107,128,141,156],"regulating":[9],"inflammation":[10],"and":[11,39,56,68,77,99,120,137,165,185],"apoptosis,":[12],"making":[13],"it":[14],"compelling":[16],"target":[17],"for":[18,45,173,179],"drug":[19],"development.":[20],"We":[21],"identified":[22],"small":[24,154],"molecule":[25,155],"inhibitor":[26],"(ML120B)":[27],"that":[28,35,148],"specifically":[29],"inhibits":[30],"IKKbeta,":[31],"an":[32],"Ikappa-B":[33],"kinase":[34],"regulates":[36],"NF-kappaB.":[37],"IKKbeta":[38,91,151,177],"are":[41],"required":[42],"vivo":[44,72,88,142,157],"prevention":[46],"of":[47,82,90,97,105,150,163,176,182],"TNFalpha-mediated":[48],"apoptosis.":[49],"ML120B":[50,93],"sensitized":[51],"mouse":[52,118],"bone":[53,75,109,132],"marrow":[54,76,110,133],"progenitors":[55],"granulocytes,":[57],"but":[58,111],"not":[59,113],"mature":[60],"B":[61,100,121,166],"cells":[62,101,122],"to":[63,125,159],"TNFalpha":[64],"killing":[65],"vitro,":[67],"induced":[69],"apoptosis":[70],"the":[74,108,180],"spleen":[78],"within":[79],"6":[80],"hours":[81],"single":[84],"oral":[85],"dose.":[86],"In":[87],"inhibition":[89,149],"with":[92,143,152],"resulted":[94],"depletion":[96,127,162],"thymocytes":[98,119],"all":[103],"stages":[104],"development":[106],"did":[112],"deplete":[114],"granulocytes.":[115],"TNF":[116],"receptor-deficient":[117],"were":[123],"resistant":[124],"ML120B-induced":[126],"vivo.":[129],"Surprisingly,":[130],"surviving":[131],"granulocytes":[134],"expressed":[135],"TNFR1":[136],"TNFR2":[138],"after":[139],"dosing":[140],"ML120B.":[144],"Our":[145],"results":[146],"show":[147],"leads":[158],"rapid":[160],"TNF-dependent":[161],"T":[164],"cells.":[167],"This":[168],"observation":[169],"has":[170],"several":[171],"implications":[172],"potential":[174],"use":[175],"inhibitors":[178],"treatment":[181],"inflammatory":[183],"disease":[184],"cancer.":[186]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2158169126","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
